UBS Maintains a 'Buy' on Watson Pharmaceuticals (WPI); Bullish on Acquisition Announcement

April 26, 2012 2:39 PM EDT Send to a Friend
Get Alerts WPI Hot Sheet
Price: $85.73 --0%

Rating Summary:
    14 Buy, 5 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 24 | Down: 17 | New: 24
Trade WPI Now!
UBS maintains a 'Buy' on Watson Pharmaceuticals (NYSE: WPI) price target raised from $71 to $80.

Analyst, Marc Goodman, said, "The pros of the deal include diversification, synergies, lower tax rate, capabilities in injectables, semi-solids, liquids, and biosimilars (insulin), low cost manuf. and CRO, and 3rd party EU dossier dev. The Actavis biz. is better than we thought. It appears $8.00 is the base case and, while we are only taking our estimate there for 2013, we could see it move north of $8.25. For 2014 we had pointed to $8.66. Now we are moving to $9.00, but we wouldn’t be surprised if 2012 end up > $9.50."

For an analyst ratings summary and ratings history on Watson Pharmaceuticals click here. For more ratings news on Watson Pharmaceuticals click here.

Shares of Watson Pharmaceuticals closed at $69.69 yesterday, with a 52 week range of $55.00-$73.35.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here



You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

UBS

Add Your Comment